Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2020

01-12-2020 | Glioma | Research article

Downregulation of S100 calcium binding protein A12 inhibits the growth of glioma cells

Authors: Chunhe Lu, Jia Liu, Mingze Yao, Lun Li, Guangyu Li

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

S100 calcium binding protein A12 (S100A12) is a member of the S100 protein family and is widely expressed in neutrophil and low expressed in lymphocytes and monocyte. However, the role of S100A12 in glioma has not yet been identified.

Methods

In the present study, we carried out immunohistochemical investigation of S100A12 in 81 glioma tissues to determine the expression of S100A12 in glioma cells, and evaluate the clinical significance of S100A12 in glioma patients. Futher we knockdown the S100A12 by shRNA, and evaluated cell proliferation, cell migration and cell apoptosis by MTT, colony formation assay, transwell assay,flow cytometry assa and western blot.

Results

We found that S100A12 was upregulated in tissues of glioma patients and the expression was correlated to WHO stage and tumor size. Further, we found that knockdown S100A12 inhibits the proliferation, migration and invasion of glioma cells through regulating cell apoptosis and EMT.

Conclusion

S100A12 plays a vital role in glioma progression, and may be an important regulatory molecule for biological behaviors of glioma cell lines.
Literature
1.
Perry A, Wesseling P. Histologic classification of gliomas. Handb Clin Neurol. 2016;134:71–95.CrossRef
2.
Ghotme KA, Barreto GE, Echeverria V, et al. Gliomas: new perspectives in diagnosis, treatment and prognosis. Curr Top Med Chem. 2017;17(12):1438–47.CrossRef
3.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.CrossRef
4.
Ferris SP, Hofmann JW, Solomon DA, Perry A. Characterization of gliomas: from morphology to molecules. Virchows Arch. 2017;471(2):257–69.CrossRef
5.
Liang J, Lv X, Lu C, et al. Prognostic factors of patients with Gliomas - an analysis on 335 patients with Glioblastoma and other forms of Gliomas. BMC Cancer. 2020;20(1):35.CrossRef
6.
Donato R, Cannon BR, Sorci G, et al. Functions of S100 proteins. Curr Mol Med. 2013;13(1):24–57.CrossRef
7.
Goyette J, Geczy CL. Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids. 2011;41(4):821–42.CrossRef
8.
Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol. 2001;69(6):986–94.PubMed
9.
Dabritz J, Langhorst J, Lugering A, et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm Bowel Dis. 2013;19(6):1130–8.CrossRef
10.
Funk S, Mark R, Bayo P, et al. High S100A8 and S100A12 protein expression is a favorable prognostic factor for survival of oropharyngeal squamous cell carcinoma. Int J Cancer. 2015;136(9):2037–46.CrossRef
11.
Thierolf M, Hagmann ML, Pfeffer M, et al. Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100A12 as potential cancer biomarker. Proteomics Clin Appl. 2008;2(1):11–22.CrossRef
12.
Jin T, Zhang Z, Yang XF, Luo JS. S100A4 expression is closely linked to genesis and progression of glioma by regulating proliferation, apoptosis, migration and invasion. Asian Pac J Cancer Prev. 2015;16(7):2883–7.CrossRef
13.
Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-Oncology. 2015;17(Suppl 4):iv1–iv62.CrossRef
14.
Wang X, Chen JX, Zhou Q, et al. Statistical report of central nervous system tumors histologically diagnosed in the Sichuan Province of China from 2008 to 2013: a West China Glioma center report. Ann Surg Oncol. 2016;23(Suppl 5):946–53.CrossRef
15.
Gross SR, Sin CG, Barraclough R, Rudland PS. Joining S100 proteins and migration: for better or for worse, in sickness and in health. Cell Mol Life Sci. 2014;71(9):1551–79.CrossRef
16.
Nazari A, Khorramdelazad H, Hassanshahi G, et al. S100A12 in renal and cardiovascular diseases. Life Sci. 2017;191:253–8.CrossRef
17.
Huang X, Zeng Y, Xing X, et al. Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection. Proteome Sci. 2014;12:22.CrossRef
18.
Li X, Lin S, Mo Z, et al. CircRNA_100395 inhibits cell proliferation and metastasis in ovarian cancer via regulating miR-1228/p53/epithelial-mesenchymal transition (EMT) axis. J Cancer. 2020;11(3):599–609.CrossRef
19.
Sun L, Fang J. Epigenetic regulation of epithelial-mesenchymal transition. Cell Mol Life Sci. 2016;73(23):4493–515.CrossRef
20.
Katsuno Y, Lamouille S, Derynck R. TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013;25(1):76–84.
21.
Bhat KP, Salazar KL, Balasubramaniyan V, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 2011;25(24):2594–609.CrossRef
22.
Mahabir R, Tanino M, Elmansuri A, et al. Sustained elevation of snail promotes glial-mesenchymal transition after irradiation in malignant glioma. Neuro-Oncology. 2014;16(5):671–85.CrossRef
23.
Yan YR, Xie Q, Li F, et al. Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells. Neuropathology. 2014;34(2):128–34.CrossRef
Metadata
Title
Downregulation of S100 calcium binding protein A12 inhibits the growth of glioma cells
Authors
Chunhe Lu
Jia Liu
Mingze Yao
Lun Li
Guangyu Li
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-06768-7

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue

Research article

Multiple HPV 16 infection with two strains: a possible marker of neoplastic progression

Research article

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

Research article

Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry

Research article

Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs

Research article

Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey

Research article

A convenient clinical nomogram for predicting the cancer-specific survival of individual patients with small-intestine adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits